AllianceBernstein
ATNM icon

AllianceBernstein’s Actinium Pharmaceuticals ATNM Stock Holding History

AllianceBernstein’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,890
Closed -$22.4K – 3239
2025
Q1 		$22.4K Hold
13,890
– – ﹤0.01% 3177
2024
Q4 		$17.5K Hold
13,890
– – ﹤0.01% 3215
2024
Q3 		$26.1K Hold
13,890
– – ﹤0.01% 3215
2024
Q2 		$103K Buy
+13,890
New +$114K ﹤0.01% 3120
2015
Q2 		– Sell
-37
Closed -$3K – 3015
2015
Q1 		$3K Hold
37
– – ﹤0.01% 3454
2014
Q4 		$6K Hold
37
– – ﹤0.01% 3347
2014
Q3 		$7K Sell
37
-36
-49% -$7.14K ﹤0.01% 3320
2014
Q2 		$16K Buy
+73
New +$24.3K ﹤0.01% 3257

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

AllianceBernstein's ATNM Position: Q2 2025 in Review

AllianceBernstein sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 13,890 shares — an estimated $22.4K sold.

AllianceBernstein first reported a position in ATNM in Q2 2014 and held it in 8 quarters. The position peaked at $103K in Q2 2024. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • AllianceBernstein reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 13,890 Actinium Pharmaceuticals shares in Q2 2025, an estimated $22.4K.
  • AllianceBernstein first reported a position in Actinium Pharmaceuticals in Q2 2014 and held it in 8 quarters.
  • AllianceBernstein's Actinium Pharmaceuticals position peaked at $103K in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.